Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Simcere Reports In-Line Q3; Takes Haircut

publication date: Nov 6, 2007
On Monday, Simcere Pharma reported sharply higher Q3 financials, but investors were not impressed, sending the stock 9% lower. However, second-thoughts on the “day after” are causing the stock to regain the entire loss and close just below $16 per share, right where it was before it released its Q3 report. By themselves, the numbers are impressive. But the numbers do no more than meet expectations, leaving investors and analysts without a happy surprise. More details...

Stock Symbol: (NYSE: SCR)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China